GSK and Flagship partner to discover novel medicines and vaccines
GSK and Flagship to jointly fund up to $150 million upfront
GSK and Flagship to jointly fund up to $150 million upfront
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Ephedrine Sulfate injection USP, 50 mg/mL is indicated for the treatment of clinically important hypotension
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Subscribe To Our Newsletter & Stay Updated